LMAT — Lemaitre Vascular Income Statement
0.000.00%
Last trade - 00:00
- $1.93bn
- $1.83bn
- $193.48m
- 100
- 10
- 99
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 117 | 129 | 154 | 162 | 193 |
Cost of Revenue | |||||
Gross Profit | 79.9 | 84.6 | 101 | 105 | 127 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 96 | 101 | 118 | 135 | 157 |
Operating Profit | 21.2 | 28.8 | 36.4 | 26.8 | 36.7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 21.7 | 27.4 | 34.3 | 27.5 | 39.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 17.9 | 21.2 | 26.9 | 20.6 | 30.1 |
Net Income Before Extraordinary Items | |||||
Net Income | 17.9 | 21.2 | 26.9 | 20.6 | 30.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 17.9 | 21.2 | 26.9 | 20.6 | 30.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.882 | 1.02 | 1.25 | 1.04 | 1.36 |
Dividends per Share |